Genetic Marker May Help Predict Risk of Ovarian Cancer
News May 28, 2012
Yale researchers had previously identified the gene known as KRAS-variant as valuable genetic marker to predict the risk of developing deadly ovarian cancer for women, however there had been conflicting evidence of its value in another study.
“This is more confirmatory evidence that this genetic test could aid women at risk of developing ovarian cancer by allowing them to make informed decisions about their health,” said Joanne B. Weidhaas, a study author and associate professor of therapeutic radiology who led the team that originally discovered the KRAS-variant.
An independent team of researchers led by scientists from Ohio State University looked for the variant in a group of women who had been diagnosed with both ovarian and breast cancer and also did not possess any other known markers for these cancers. The study found 39 percent of women in the study possessed the variant.
Other studies have also shown that the variant predicts how well patients respond to standard forms of chemotherapy and the outcome of their disease.
CMC Biologics Announces Development and Manufacturing Agreement with Harpoon TherapeuticsNews
Companies have entered into agreement for the development and manufacturing of three TriTAC molecules for the treatment of cancers.READ MORE
Some Immune Cells May Help Tumors Instead of Destroying ThemNews
New data shows that neutrophils promote tumor progression and can actually hamper the work of immunotherapy in lung cancer.READ MORE